Skip to main content

Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant

Buy Article:

$43.00 plus tax (Refund Policy)

Background: To evaluate whether the risk of methotrexate (MTX) exposure through skin contamination using parenteral doses of 25 mg warrants special oncology handling precautions during administration.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: handling precautions; methotrexate; rheumatoid arthritis; skin contamination; toxicity

Document Type: Research Article

Publication date: 2009-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more